Top

Published in:

01-10-2008 | Epidemiology

A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk

Authors: Kathryn E. Talbott, Marilie D. Gammon, Muhammad G. Kibriya, Yu Chen, Susan L. Teitelbaum, Chang-Min Long, Irina Gurvich, Regina M. Santella, Habibul Ahsan

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Due to the established association between estrogen levels and breast cancer risk, polymorphic variation in genes regulating estrogen levels is thought to be related to breast cancer risk. Aromatase, the protein product of the CYP19 gene, is involved in the production of endogenous estrogens via androgen conversion. We examined whether polymorphic variation in CYP19 associated with increased breast cancer risk in a population based case-control study. We examined two single nucleotide polymorphisms (SNP), rs1008805 (A/G) and rs730154 (C/T), which have been shown to tag SNPs within two different haplotype blocks in CYP19. Among premenopausal women, the presence of at least one G allele at rs1008805 was significantly associated with an increase in the risk of breast cancer (OR = 1.72 [95% CI, 1.20–2.49]), especially with estrogen and progesterone receptor negative breast cancer (OR = 3.89 [1.74–8.70] and OR = 2.52 [1.26–5.05], respectively). No association was observed among postmenopausal women (OR = 1.06 [0.82–1.36]). There was no significant association between rs730154 and breast cancer, regardless of menopausal status. Our results suggest that premenopausal women carrying the G allele at CYP19 rs1008805 have increased risk of breast cancer. The finding supports the potential role of variation in estrogen biosynthesis genes in premenopausal breast cancer risk.

Mahendroo MS, Means GD, Mendelson CR et al (1991) Tissue-specific expression of human P450 AROM. J Biol Chem 266(17):11276–11281PubMed

Hunter DJ, Willett WC (1993) Diet, body size, and breast cancer. Epidemiol Rev 15(1):110–132PubMed

Bulun S, Lin Z, Imir G et al (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57:359–383PubMedCrossRef

Chetrite G, Cortes-Prieto J, Philippe J et al (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27PubMedCrossRef

Tekmal R, Kirma N, Gil K et al (1999) Aromatase overexpression and breast hyperplasia, an in vivo model–continued overexpression of aromatase is sufficient to maintain hyperplasis without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocrine-Related Cancer 6(2):307–314PubMedCrossRef

Goss PE, Strasser K (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19(3):881–894PubMed

Somner J, McLellan S, Cheung J et al (2004) Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) Genes: Association with Serum Sex Steroid Concentrations and Bone Mineral Density in Postmenopausal Women. J Clin Endocrinol & Metabol 89(1):344–351CrossRef

Carani C, Qin K, Simoni M et al (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. New Engl J Med 337(2):91–95PubMedCrossRef

Ito Y, Fisher CR, Conte FA et al (1993) Molecular basis of aromatase deficiency in an adult female with sexual infantalism and polycystic ovaries. Proc Natl Acad Sci USA 90(24):11673–11677PubMedCrossRef

10.

Morishima A, Grumbach MM, Simpson ER et al (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metabol 80(12):3689–3698CrossRef

11.

Mullis PE, Yoshimura N, Kuhlman B et al (1997) Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metabol 82(6):1739–1745CrossRef

12.

Henderson B, Feigelson H (2000) Hormonal carcinogenesis. Carcinogenesis 21(3):427–433PubMedCrossRef

13.

Haiman CA, Hankinson SE, Spiegelman D et al (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87(2):204–210PubMedCrossRef

14.

Healey CS, Dunning AM, Durocher F et al (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21(2):189–193PubMedCrossRef

15.

Kristensen VN, Andersen TI, Lindblom A et al (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8(1):43–48PubMedCrossRef

16.

Probst-Hensch NM, Ingles SA, Diep AT et al (1999) Aromatase and breast cancer susceptibility. Endocrine-Related Cancer 6(2):165–173PubMedCrossRef

17.

Siegelmann-Danieli N, Buetow KH (1999) Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk. Brit J Cancer 79(3–4):456–463PubMedCrossRef

18.

Ahsan H, Whittemore AS, Chen Y et al (2004) Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 7(1):R71–R81PubMedCrossRef

19.

Baxter SW, Choong DY, Eccles DM et al (2001) Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 22(2):347–349PubMedCrossRef

20.

Dunning AM, Dowsett M, Healey CS et al (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96(12):936–945PubMedCrossRef

21.

Hirose K, Matsuo K, Toyama T et al (2004) The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomark Prev 13(8):1407–1411

22.

Miyoshi Y, Iwao K, Ikeda N et al (2000) Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 89(4):325–328PubMedCrossRef

23.

Thyagarajan B, Brott M, Mink P et al (2004) CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 207(2):183–189PubMedCrossRef

24.

Haiman CA, Stram DO, Pike MC et al (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 12(20):2679–2692PubMedCrossRef

25.

Gammon MD, Neugut AI, Santella RM et al (2002) The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 74(3):235–254PubMedCrossRef

26.

Stephens M, Smith N, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978–989PubMedCrossRef

27.

Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(5):1162–1169PubMedCrossRef

28.

Chong Y, Colston K, Jiang W et al (2006) The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 99:275–288PubMedCrossRef

29.

Hankinson S, Willett W, Colditz G et al (1998) Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRef

30.

Pharoah PD, Dunning AM, Ponder BAJ et al (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4(11):850–860PubMedCrossRef

31.

Bond GL, Hu W, Bond EE et al (2004) A Single Nucelotide Polymorphism in the MDM2 PromoterAttenuates the p53 Tumor Supressor Pathway and Accellerates Tumor Formation in Humans. Cell 119:591–602PubMedCrossRef

32.

Skorupski P, Krol J, Starega J et al (2006) An alpha-1 chain of type 1 collagen Sp1-binding site polymorphism in women suffering from stress urinary incontinence. Am J Obstet Gynecol 194(2):346–350PubMedCrossRef

33.

Lian K, Zmuda JM, Nevitt MC et al (2005) Type I collagen alpha1 Sp1 transcription factor binding site polymorphism is associated with reduced risk of hip osteoarthritis defined by severe joint space narrowing in elderly women. Arthritis Rheum 52(5):1431–1436PubMedCrossRef

34.

Duan J, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216PubMedCrossRef

35.

Jin Y, Dietz HC, Montgomery RA et al (1996) Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. J Clin Invest 98(8):1745–1754PubMedCrossRef

36.

Chen X, Truong TT, Weaver J et al (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27(5):427–435PubMedCrossRef

37.

International HapMap Project. http://www.hapmap.org

38.

Haiman CA, Dossus L, Setiawan VW et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893–1897PubMedCrossRef

Title: A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk
Authors: Kathryn E. Talbott
Marilie D. Gammon
Muhammad G. Kibriya
Yu Chen
Susan L. Teitelbaum
Chang-Min Long
Irina Gurvich
Regina M. Santella
Habibul Ahsan
Publication date: 01-10-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9794-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

ERCC1 expression in triple negative breast carcinoma: the paradox revisited

Tumor-derived CCL5 does not contribute to breast cancer progression

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas

Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

A polymorphism in the G protein β3-subunit gene is associated with bone metastasis risk in breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer